---
figid: PMC9539985__TAP-26-679-g007
pmcid: PMC9539985
image_filename: TAP-26-679-g007.jpg
figure_link: /pmc/articles/PMC9539985/figure/tap13820-fig-0001/
number: FIGURE 1
figure_title: ''
caption: Hypoxia‐inducible factor (HIF) pathway and roles of HIF in erythropoiesis
  and iron metabolism. Figure modified from fig. 3 in Koury et al. and fig. 1 in Sugahara
  et al. HIF‐PHi, hypoxia‐inducible factor prolyl hydroxylase inhibitor; pVHL, von
  Hippel–Lindau protein; Ub, ubiquitin; EPO, erythropoietin; TF, transferrin; Dcytb,
  duodenal cytochrome b; DMT1, divalent metal transporter 1; FPN, ferroportin
article_title: 'Treatment of anemia associated with chronic kidney disease with the
  HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.'
citation: Ryo Fujikawa, et al. Ther Apher Dial. 2022 Aug;26(4):679-693.
year: '2022'

doi: 10.1111/1744-9987.13820
journal_title: Therapeutic Apheresis and Dialysis
journal_nlm_ta: Ther Apher Dial
publisher_name: John Wiley & Sons Australia, Ltd

keywords:
- anemia in chronic kidney disease
- enarodustat
- erythropoietin
- HIF‐PH inhibitor
- iron utilization

---
